Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17719247 | 1.00 | POLRMT (0.31) | POLRMT | |
| SCHEMBL26313337 | 0.85 | TMPRSS2 (0.35) | — | |
| SCHEMBL26206775 | 0.85 | TMPRSS2 (0.35) | — | |
| SCHEMBL17712280 | 0.83 | — | — | |
| SCHEMBL10120675 | 0.82 | TNK2 (0.35) | POLRMT | |
| SCHEMBL10120838 | 0.82 | TNK2 (0.35) | POLRMT | |
| SCHEMBL17719386 | 0.82 | TNK2 (0.35) | POLRMT | |
| SCHEMBL18371662 | 0.82 | TNK2 (0.35) | POLRMT | |
| SCHEMBL4765229 | 0.82 | POLRMT (0.30) | POLRMT | |
| SCHEMBL17719373 | 0.79 | TMPRSS2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | POLRMT 49/4885 |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | POLRMT 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.